Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Bowen

Showing results (61-70 of 96) with videos related to

Pageof 10
Sort By:
British Journal of Haematology|May 21, 2024
Inflammatory profile of lower risk myelodysplastic syndromesJoanne Topping, Adele Taylor, Fatima Nadat, et al.
British Journal of Haematology|November 6, 2022
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registryKrzysztof Mądry, Karol Lis, Pierre Fenaux, et al.
European Journal of Haematology|May 13, 2014
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 studyAristoteles Giagounidis, Ghulam J Mufti, Moshe Mittelman, et al.
The Lancet. Haematology|February 5, 2025
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort studyHege Kristin Gravdahl Garelius, Timothy Bagguley, Adele Taylor, et al.
Annals of Hematology|May 21, 2017
Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordanceLouise de Swart, Alex Smith, Marius MacKenzie, et al.
Blood|July 15, 2011
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5qPierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, et al.
British Journal of Haematology|October 2, 2014
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromesFabio Efficace, Gianluca Gaidano, Massimo Breccia, et al.
BMJ Open|February 22, 2024
PRECISION-TBI: a study protocol for a vanguard prospective cohort study to enhance understanding and management of moderate to severe traumatic brain injury in AustraliaToby Jeffcote, Camila R Battistuzzo, Mark P Plummer, et al.
Blood|August 28, 2013
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetLuca Malcovati, Eva Hellström-Lindberg, David Bowen, et al.
Haematologica|November 11, 2017
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Chloé Reiniers, Timothy Bagguley, et al.
Pageof 10

Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
British Journal of Haematology|May 21, 2024
Inflammatory profile of lower risk myelodysplastic syndromesJoanne Topping, Adele Taylor, Fatima Nadat, et al.
British Journal of Haematology|November 6, 2022
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registryKrzysztof Mądry, Karol Lis, Pierre Fenaux, et al.
European Journal of Haematology|May 13, 2014
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 studyAristoteles Giagounidis, Ghulam J Mufti, Moshe Mittelman, et al.
The Lancet. Haematology|February 5, 2025
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort studyHege Kristin Gravdahl Garelius, Timothy Bagguley, Adele Taylor, et al.
Annals of Hematology|May 21, 2017
Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordanceLouise de Swart, Alex Smith, Marius MacKenzie, et al.
Blood|July 15, 2011
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5qPierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, et al.
British Journal of Haematology|October 2, 2014
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromesFabio Efficace, Gianluca Gaidano, Massimo Breccia, et al.
BMJ Open|February 22, 2024
PRECISION-TBI: a study protocol for a vanguard prospective cohort study to enhance understanding and management of moderate to severe traumatic brain injury in AustraliaToby Jeffcote, Camila R Battistuzzo, Mark P Plummer, et al.
Blood|August 28, 2013
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetLuca Malcovati, Eva Hellström-Lindberg, David Bowen, et al.
Haematologica|November 11, 2017
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Chloé Reiniers, Timothy Bagguley, et al.
Pageof 10